Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
OCGN

OCGN - Ocugen Inc Stock Price, Fair Value and News

$1.55-0.04 (-2.52%)
Market Closed

9/100

OCGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

9/100

OCGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.33

Target 3M

$1.49

Target 6M

$1.41

OCGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OCGN Price Action

Last 7 days

4.0%

Last 30 days

4.7%

Last 90 days

4.7%

Trailing 12 Months

118.3%

OCGN RSI Chart

OCGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OCGN Valuation

Market Cap

484.1M

Price/Earnings (Trailing)

-7.56

Price/Sales (Trailing)

90.15

EV/EBITDA

-6.35

Price/Free Cashflow

-9.04

OCGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.33

Target 3M

$1.49

Target 6M

$1.41

OCGN Fundamentals

OCGN Revenue

Revenue (TTM)

5.4M

Rev. Growth (Yr)

54.23%

Rev. Growth (Qtr)

27.6%

OCGN Earnings

Earnings (TTM)

-64.0M

Earnings Growth (Yr)

-54.6%

Earnings Growth (Qtr)

-36.04%

OCGN Profitability

EBT Margin

-1289.55%

Return on Equity

-1.8K%

Return on Assets

-111.15%

Free Cashflow Yield

-11.06%

OCGN Investor Care

Shares Dilution (1Y)

7.21%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.5M4.8M5.4M0
20246.6M7.3M4.7M4.1M
20232.4M2.3M5.5M6.0M
2022654.3K1.3M1.9M2.5M
202000043.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Ocugen Inc

OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
 CEO
 WEBSITEocugen.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES84

Ocugen Inc Frequently Asked Questions

OCGN is the stock ticker symbol of Ocugen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Ocugen Inc is 484.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check OCGN's fair value in chart for subscribers.

The fair value guage provides a quick view whether OCGN is over valued or under valued. Whether Ocugen Inc is cheap or expensive depends on the assumptions which impact Ocugen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCGN.

As of Wed Jan 28 2026, OCGN's PE ratio (Price to Earnings) is -7.56 and Price to Sales (PS) ratio is 90.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCGN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Ocugen Inc has provided -0.379 (multiply by 100 for percentage) rate of return.